Peter Attia· MD
as you move from the 2 to the 3 to the 4 you see LP little a go up you see a poby go up and you see triglyceride go down and this is a pattern that has been demonstrated over and over and over again
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
as you move from the 2 to the 3 to the 4 you see LP little a go up you see a poby go up and you see triglyceride go down and this is a pattern that has been demonstrated over and over and over again
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
does the association with APO E4 in terms of risk vanish once you normalize for apob or is there still residual risk based on these other factors such as inflammation that exist and persist once you've normalized for apo3 versus apo4 in the context of the same ldlc slash apob